Cisplatine Teva 1 mg/ml solution à diluer pour perfusion.

DRUG3 trials

Sponsors

Gilead Sciences Inc., Asso De Recherche Cancers Gynecologiques, Fondation Franc.Cancerologie Digestive

Conditions

Advanced Non-Small Cell Lung CancerHihg risk of cholangiocarcinoma intra hépatic resectablePatients with a confirmed diagnosis of ovarian small cell carcinoma.

Phase 2

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

Active, not recruitingCTIS2022-502916-35-01

Gilead Sciences Inc.Advanced Non-Small Cell Lung Cancer

Start: 2024-03-27Target: 171Updated: 2025-09-10

Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ovarian carcinoma of hypercalcemic type

RecruitingCTIS2024-515310-40-01

Asso De Recherche Cancers GynecologiquesPatients with a confirmed diagnosis of ovarian small cell carcinoma.

Start: 2021-08-04Target: 27Updated: 2026-01-22

PRODIGE 118 - PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Phase II single arm study -mutlicenter

RecruitingCTIS2025-521302-17-00

Fondation Franc.Cancerologie DigestiveHihg risk of cholangiocarcinoma intra hépatic resectable

Start: 2026-01-12Target: 49Updated: 2025-10-15